Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

All three major indices are trading up today with the

Dow Jones Industrial Average

(

^DJI

) trading up 114 points (0.6%) at 17,744 as of Wednesday, July 29, 2015, 2:00 PM ET. The NYSE advances/declines ratio sits at 2,136 issues advancing vs. 880 declining with 147 unchanged.

The Health Services industry currently sits up 0.3% versus the S&P 500, which is up 0.5%. Top gainers within the industry include

NuVasive

(

NUVA

), up 9.9%,

Quintiles Transnational Holdings

(

Q

), up 4.1%,

Waters

(

WAT

), up 2.2% and

Quest Diagnostics

(

DGX

), up 1.3%.

TheStreet would like to highlight 3 stocks pushing the industry lower today:

3.

Boston Scientific

(

BSX

) is one of the companies pushing the Health Services industry lower today. As of noon trading, Boston Scientific is down $0.23 (-1.3%) to $17.28 on light volume. Thus far, 3.2 million shares of Boston Scientific exchanged hands as compared to its average daily volume of 9.2 million shares. The stock has ranged in price between $17.28-$17.57 after having opened the day at $17.52 as compared to the previous trading day's close of $17.51.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. The company operates in three segments: Cardiovascular, Rhythm Management, and MedSurg. Boston Scientific has a market cap of $22.9 billion and is part of the health care sector. Shares are up 32.1% year-to-date as of the close of trading on Tuesday. Currently there are 14 analysts that rate Boston Scientific a buy, 1 analyst rates it a sell, and 7 rate it a hold.

TheStreet Ratings rates

Boston Scientific

as a

buy

. The company's strengths can be seen in multiple areas, such as its solid stock price performance, increase in net income, largely solid financial position with reasonable debt levels by most measures and expanding profit margins. We feel its strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full

Boston Scientific Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

2. As of noon trading,

Edwards Lifesciences

(

EW

) is down $4.56 (-2.9%) to $151.24 on heavy volume. Thus far, 1.1 million shares of Edwards Lifesciences exchanged hands as compared to its average daily volume of 1.1 million shares. The stock has ranged in price between $150.75-$159.00 after having opened the day at $154.85 as compared to the previous trading day's close of $155.80.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Edwards Lifesciences Corporation provides products and technologies to treat structural heart disease and critically ill patients worldwide. Edwards Lifesciences has a market cap of $16.4 billion and is part of the health care sector. Shares are up 22.3% year-to-date as of the close of trading on Tuesday. Currently there are 12 analysts that rate Edwards Lifesciences a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates

Edwards Lifesciences

as a

buy

. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity and expanding profit margins. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Edwards Lifesciences Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

1. As of noon trading,

Humana

(

HUM

) is down $2.02 (-1.1%) to $182.50 on light volume. Thus far, 667,389 shares of Humana exchanged hands as compared to its average daily volume of 2.9 million shares. The stock has ranged in price between $182.30-$184.89 after having opened the day at $183.84 as compared to the previous trading day's close of $184.52.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Humana Inc., together with its subsidiaries, operates as a health and well-being company. The company operates through three segments: Retail, Group, and Healthcare Services. Humana has a market cap of $27.5 billion and is part of the health care sector. Shares are up 28.5% year-to-date as of the close of trading on Tuesday. Currently there are 5 analysts that rate Humana a buy, no analysts rate it a sell, and 11 rate it a hold.

TheStreet Ratings rates

Humana

as a

buy

. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, solid stock price performance, increase in net income and reasonable valuation levels. We feel its strengths outweigh the fact that the company shows weak operating cash flow. Get the full

Humana Ratings Report

now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health services industry could consider

Health Care Select Sector SPDR

(

XLV

) while those bearish on the health services industry could consider

ProShares Ultra Short Health Care

(

RXD

).